Parkinson's Disease Trial, Recruiting NCT07441915 Sponsor: University of Zurich Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT07441915
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been clinically diagnosed with Parkinson's disease, based on recognised medical guidelines
  • People who have mild cognitive impairment (MCI) related to Parkinson's disease, meaning a gradual decline in thinking or memory noticed by the person themselves, a family member, or a doctor
  • People whose score on a standard memory and thinking test (called the MoCA) falls between 18 and 26
  • People who have a stable living situation that would allow them to consistently take part in the study's activities for its full duration
  • People who are able to follow the sleep-related part of the study on their own, or with the help of someone they live with
  • People who are able to complete the thinking and memory training exercises for the full length of the study
  • People who have a good enough understanding of German to follow the study procedures and answer all study-related questions
  • People whose Parkinson's medications and other related treatments have remained unchanged for at least 14 days before the study begins, and are expected to stay the same until the study ends

Who may not be able to join:

  • People who have been diagnosed with dementia, meaning cognitive difficulties that significantly affect their ability to manage day-to-day activities independently
  • People with a known neurological condition other than Parkinson's disease, or a known psychiatric condition
  • People whose Parkinson's-like symptoms do not respond to the medication levodopa, or who have been assessed as having an atypical Parkinson's condition
  • People with serious medical conditions such as kidney failure, liver failure, or severe heart failure (confirm with trial site)
  • People who regularly use benzodiazepines or other medications that slow down the central nervous system
  • People with known or suspected misuse of drugs or medications
  • People who consume more than half a litre of wine or one litre of beer per day
  • People with moderate-to-severe obstructive sleep apnea (a breathing condition during sleep), with an apnea-hypopnea index above 15 and a recommendation for treatment, or who currently use a CPAP breathing machine — though some milder or REM-related sleep apnea cases may still be considered eligible (confirm with trial site)
  • People with Restless Legs Syndrome
  • People who experience non-REM sleep disturbances (a type of sleep disorder involving unusual behaviours during sleep) at least once a week — note that sleep problems commonly linked to Parkinson's disease, such as REM sleep behaviour disorder, insomnia, or nighttime Parkinson's symptoms, do not automatically exclude someone
  • People who are unable to hear the tones produced by the sleep headband device used in the study
  • People whose brains do not show a detectable response to the sound-based sleep stimulation during screening (confirm with trial site)
  • People with skin conditions, sensitivities, or allergies around the face or ears that could be made worse by wearing electrodes
  • People who are thought to be unlikely to follow the study requirements
  • People who are unable to follow study procedures due to language difficulties or cognitive challenges
  • People who do not or cannot give informed consent to participate
  • People who have taken part in another study involving an investigational treatment within the past 30 days (for the sleep component) or within the past year (for the cognitive training component), or who plan to do so during this study
  • People who have previously been enrolled in this same study
  • Investigators running the study, along with their family members, employees, or anyone else in a dependent relationship with them
  • People who work night shifts
  • People who have travelled across more than two time zones in the month before the study begins, or who plan to do so during the study — though the trial site notes that the start date may be adjusted to accommodate this
  • People who have a significant medical procedure planned during the study, such as surgery — routine check-ups are generally permitted
  • Women who are pregnant or breastfeeding
  • Women who intend to become pregnant during the study
  • Women of childbearing potential who are not using, and are not willing to use, a reliable method of contraception for the full duration of the study — note that women who have been surgically sterilised, had a hysterectomy, or have been post-menopausal for more than one year are not considered to be of childbearing potential for the purposes of this criterion

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Simon J. Schreiner, MD, University Hospital Zurich, University of Zurich

Phone: +41 43 253 24 18

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
22 April 2026
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Additive Effect of PTAS on Cognitive Improvements (Executive Performance) Through Digital Cognitive Training in PD-MCI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov